Barclays’s Aurinia Pharmaceuticals AUPH Stock Holding History

Barclays’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-42,500	Closed	-$213K	–	4863
2024 Q1	$213K	Buy	42,500 +9,500	+29%	+$64.4K	﹤0.01%	4087
2023 Q4	$297K	Buy	+33,000	New	+$272K	﹤0.01%	4213
2022 Q1	–	Sell	-31,200	Closed	-$714K	–	4939
2021 Q4	$714K	Buy	+31,200	New	+$739K	﹤0.01%	3018
2020 Q1	–	Sell	-9,900	Closed	-$201K	–	6127
2019 Q4	$201K	Sell	9,900 -132,600	-93%	-$1.22M	﹤0.01%	5023
2019 Q3	$761K	Buy	+142,500	New	+$862K	﹤0.01%	3900
2019 Q1	–	Sell	-50,000	Closed	-$341K	–	6993
2018 Q4	$341K	Hold	50,000	–	–	﹤0.01%	4168
2018 Q3	$332K	Buy	+50,000	New	+$280K	﹤0.01%	4600

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's AUPH Position: Q2 2026 in Review

Barclays reduced its Aurinia Pharmaceuticals (AUPH) stake by 7% in Q2 2026, selling an estimated $33.7K and leaving 27,892 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #3263.

Barclays first reported a position in AUPH in Q2 2017 and has held it in 34 quarters since. The position peaked at $13.2M in Q3 2021. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Barclays held 27,892 shares of Aurinia Pharmaceuticals worth $473K as of Q2 2026.
Barclays sold 2,108 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $33.7K.
Aurinia Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3263 holding.
Barclays first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 34 quarters since.
Barclays's Aurinia Pharmaceuticals position peaked at $13.2M in Q3 2021.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.